Needle-free Drug Delivery Technology Market Size, Share and Global Trend By Product (Inhaler, Jet Injector, Novel Needles, Transdermal Patch), By Application ( Vaccine Delivery, Pain Management, Insulin Delivery), By End Users (Hospitals & Clinics, Homecare Settings, Research Laboratories, Academics), and Regional Forecast, 2024-2032

Needle-free drug delivery devices are a novel way to introduce various drugs such as medicines into patients by avoiding piercing the skin with a needle. Needle-free devices offer the obvious benefit to the patient of not using a syringe or needle, which may be used or contaminated. Needle-free drug delivery devices offer a wide range of advantages such as the direct introduction of drugs into the bloodstream as compared to other alternatives, ensuring of proper dosage, faster administration, affordability, less painful and improved outcomes.

Needle-free drug delivery devices can be used for a range of diseases such as diabetes, infectious and chronic diseases such as AIDS, hepatitis, cholera, malaria, rheumatoid arthritis, and vaccinations. In emerging regions such as Africa, the high incidences of chronic and infectious diseases such as AIDS, West Nile Virus, hepatitis, malaria, and neurological diseases. To avoid infections or contamination there is a need for drug delivery devices free of the risk of contamination. Needle-free drug delivery devices are an effective solution for such issues. The World Health Organization (WHO) estimated that in Africa in 2015, close to 26 million people were living with HIV, of whom 2.3 million were children under the age of 15 years and 90% of these children lived in Sub-Saharan Africa. These factors combined are expected to contribute significantly towards the growth of this market.

To gain extensive insights into the market, Request for Customization

One of the key drivers of the growth in the market is the number of advantages associated with the needle-free drug delivery technology market. Some of the advantages include the administration of the accurate dosage, the less painful and improved patient outcomes, the faster administration resulting in the faster effect of the drugs on the body and the affordability associated with it. These factors are resulting in greater R&D initiatives resulting in greater and considerable growth of the market.

The factor that is expected to inhibit the growth of the market is the stringent regulatory framework for the approval of needle-free drug delivery products. Another factor that might limit the growth of the market is the certain limitations associated with the micro dermal patches.

Key Players Covered

Some of the major companies that are present in the global needle-free drug delivery technology markets are Zogenix, Inc., 3M, Antares Pharma, Injex Pharma AG, PharmaJet, Bioject Medical Technologies, Inc., Endo Pharmaceuticals Inc. and other players.

SEGMENTATION

At present, jet injector accounted for the largest proportion of the market, due to the number of associated advantages over the traditional forms of drug delivery such as the faster drug delivery into the bloodstream and the usage of the technology over a wider range of applications.

Key Insights

• Overview of opportunity assessment in untapped markets


• Advancements in research & development of needle-free drug delivery technology


• Key industry developments


• New product launches


• Cost of development of technology


• Regulatory scenario by key countries

• Regional Analysis

The global needle-free drug delivery technology market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Europe are the two largest markets for needle-free drug delivery technology at present and they are expected to account for a large proportion of the market in the forecast period as well. This is due to the high prevalence of the chronic and acute diseases in the region, the ongoing research & development initiatives for the treatment options and the increasing demand for technologically advanced drug delivery systems for better outcomes. In the Asia Pacific region, Japan is expected to provide the largest market opportunity. This is because Japan has a highly developed healthcare infrastructure demanding the most technologically advanced systems and the higher proportion of geriatric population requiring systems with better patient outcomes.

Key Industry Developments

• In October 2018, PharmaJet was recognized with the 2018 Global Technology Innovation Award for its needle-free drug delivery technology


• In July 2018, the Food and Drug Administration (FDA) gave the regulatory approval to Ferring Pharmaceuticals for its injectable somatropin product, following which the company plans to launch the needle-free drug delivery technology system


• In December 2017, the MIT spinoff startup Portal Instruments entered into a commercialization deal for its needle free drug delivery technology